Summary of baseline patient demographic and disease characteristics
| Characteristic . | All patients (N = 203) . |
|---|---|
| Sex, n (%) | |
| Male | 100 (49.3) |
| Female | 103 (50.7) |
| Race, n (%) | |
| White | 164 (80.8) |
| Asian | 12 (5.9) |
| Black or African American | 11 (5.4) |
| Other | 16 (7.9) |
| Age, median (IQR), y | 10.0 (6.0-13.0) |
| Age group, n (%) | |
| ≥1 to <6 y | 49 (24.1) |
| ≥6 to <12 y | 81 (39.9) |
| ≥12 to <18 y | 73 (36.0) |
| Time since ITP diagnosis, median (IQR), y∗ | 1.8 (1.0-3.8) |
| Age at ITP diagnosis, median (IQR), y | 6.0 (3.6-10.2) |
| Platelet count, median (IQR), ×109/L | 14.0 (7.0-23.5) |
| Platelet counts >30 × 109/L during screening, n (%) | 13 (6.4) |
| Previous splenectomy, n (%) | 10 (4.9) |
| Time since splenectomy, median (IQR), y∗ | 3.9 (2.6-7.3) |
| No. of prior ITP treatments, median (IQR) | 2.0 (2.0-3.0) |
| Selected prior ITP treatments, n (%) | |
| Rituximab | 27 (13.3) |
| Eltrombopag | 7 (3.4) |
| Mycophenolate | 1 (0.5) |
| Characteristic . | All patients (N = 203) . |
|---|---|
| Sex, n (%) | |
| Male | 100 (49.3) |
| Female | 103 (50.7) |
| Race, n (%) | |
| White | 164 (80.8) |
| Asian | 12 (5.9) |
| Black or African American | 11 (5.4) |
| Other | 16 (7.9) |
| Age, median (IQR), y | 10.0 (6.0-13.0) |
| Age group, n (%) | |
| ≥1 to <6 y | 49 (24.1) |
| ≥6 to <12 y | 81 (39.9) |
| ≥12 to <18 y | 73 (36.0) |
| Time since ITP diagnosis, median (IQR), y∗ | 1.8 (1.0-3.8) |
| Age at ITP diagnosis, median (IQR), y | 6.0 (3.6-10.2) |
| Platelet count, median (IQR), ×109/L | 14.0 (7.0-23.5) |
| Platelet counts >30 × 109/L during screening, n (%) | 13 (6.4) |
| Previous splenectomy, n (%) | 10 (4.9) |
| Time since splenectomy, median (IQR), y∗ | 3.9 (2.6-7.3) |
| No. of prior ITP treatments, median (IQR) | 2.0 (2.0-3.0) |
| Selected prior ITP treatments, n (%) | |
| Rituximab | 27 (13.3) |
| Eltrombopag | 7 (3.4) |
| Mycophenolate | 1 (0.5) |
Years since diagnosis are calculated from the time of the screening visit.